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Abstract 
Versican, a ubiquitous component of the extracellular matrix (ECM), accumulates both in 
tumor stroma and cancer cells and is highly regulated by various cytokines. The aberrant 
expression of versican and its isoforms is known to modulate cell proliferation, differentiation, 
and migration, all of which are features of the invasion and metastasis of cancer; versican is 
also known to favour the homeostasis of the ECM. Interleukin-11 (IL-11) is an important 
cytokine that exhibits a wide variety of biological effects in gastric cancer development. Here, 
we analysed the expression of versican isoforms and found that the major isoforms expressed 
by both gastric carcinoma tissue and gastric cell lines were V0 and V1, and V1 was significantly 
higher in gastric carcinoma tissue. The treatment of the gastric cell lines AGS and MKN45 
with rhIL-11 resulted in a significant increase in the expression of V0 and V1. Exogenous IL-11 
increased migration in AGS and MKN45 cells, whereas these effects were reversed when the 
expression of V0 and V1 were abolished by siRNA targeting versican V0/V1. Collectively, 
these findings suggest that the abnormally expressed versican and its isoforms participate, at 
least in part, in the progress of gastric carcinoma triggered by IL-11. 
Key words: Versican; IL-11; gastric carcinoma; migration. 
Introduction 
Gastric carcinoma, the fourth most common ma-
lignancy and the second most frequent cause of cancer 
death, is the result of accumulated genomic damage, 
affecting  cellular  functions  essential  for  cancer  de-
velopment[1,  2].  A  considerable  body  of  evidence 
suggests that the tumour environment is one of the 
major factors that determine the behaviour of malig-
nant cells. Additionally, the tumour cell invasion and 
subsequent metastasis, which are complex and mul-
ti-step mechanisms are critical steps in the progres-
sion  of  malignant  tumours,  including  gastric  carci-
noma. 
The extracellular matrix (ECM), which is mainly 
composed of proteoglycans, glycoproteins and colla-
gens, is a complex structural entity surrounding and 
supporting  cells  within  tissues  and  playing  many 
physiological and pathological roles. The ECM main-
tains tissue integrity and homeostasis and provides a 
Ivyspring  
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reservoir of cytokines and growth factors. Modifica-
tion of the ECM composition through a large array of 
molecules  and  cell-cell  and  cell-matrix  interactions 
may  be  crucial  for  tumour  initiation  and  progres-
sion[3]. 
Versican is an ECM molecule, and it accumulates 
both in tumour stroma and cancer cells[4]. It is known 
to  modulate  cell  proliferation,  differentiation,  adhe-
sion, and migration, all of which are features of the 
invasion  and  metastasis  of  cancer,  and  versican  is 
known to favour the homeostasis of ECM[4, 5]. Thus, 
this molecule may play a wide range of roles in the 
invasion and metastasis of tumour cells. Structurally, 
versican  consists  of  N-and  C-terminal  globular  do-
mains and two chondroitin sulphate domains (CS-α 
and CS-β), which are encoded by differential splicing 
exons.  Alternative  splicing  generates  at  least  four 
isoforms of versican, known as V0, V1, V2, and V3[6]. 
V0 contains both CS-α and CS-β; V1 and V2 possess 
only CS-β and CS-α, respectively; and V3 has only the 
globular domains. The versican V0 and V1 isoforms 
are mainly expressed in the late stage of embryonic 
development[7], whereas V2 is one of the main con-
stituents of the mature neural ECM[8]. By virtue of its 
differing  domains  and  motifs,  versican  binds  to  a 
number of molecules in the ECM such as hyaluronan, 
type I collagen, tenascin-R, fibulin-1, and -2, fibrillin-1, 
fibronectin, P- and L-selectins, and chemokines[9-14], 
and interacts with the cell surface proteins epidermal 
growth factor receptor (EGFR), CD44, integrin β1, and 
P-selectin  glycoprotein  ligand-1[15,  16].  As  a  large 
member of the lectican family of proteoglycans, ver-
sican also affects the cytokeleton rearrangement and 
assembly[17].  Moreover,  the  versican  conditional 
knock-out mice exhibit distorted digits and delayed 
cartilage development[18].  
The literature spanning the last decade has as-
certained  a  significant  involvement  of  versican  in 
tumour  progression.  An  increased  concentration  of 
versican may be obligatory for angiogenesis and me-
tastasis in tumours[19]. A number of reports within 
the  last  few  years  have  identified  a  significant  in-
volvement of versican in gastric carcinomas: one re-
port provided evidence that the level of versican in 
gastrointestinal  stromal  tumours  was  significantly 
higher, and the highly expressed protein was corre-
lated  with  poor  disease-free  survival[20].  From  an 
analysis of Δ-disaccharides, it was observed that ver-
sican  expression  was  significantly  increased  by  ap-
proximately 3-fold in human gastric carcinomas[21]. 
Naohide Oue et al. determined that versican was ex-
pressed  at  much  lower  levels  in  tumour-associated 
stromal areas of atomic-bomb-exposed patients than 
in non-exposed patients[1]. Additionally, the genetic 
variants A1826H and D2937Y in the GAG-β domain of 
versican could influence a patient’s susceptibility to 
intestinal-type gastric cancer[22]. 
Studies to date have identified a number of cy-
tokines  or  growth  factors  such  as  transforming 
growth factors β2 and β3 (TGF-β2 and TGF-β3), basic 
fibroblast  growth  factor  (bFGF),  platelet-derived 
growth  factor  BB  (PDGF-BB),  and  interleukin-1β 
(IL-1β), that regulate the synthesis of versican[23-25], 
and  among  these  factors,  IL-1β  down-regulates  the 
expression  of  versican  in  arterial  smooth  muscle 
cells[25]. However, because the related data remain 
limited and fragmentary, it is nebulous to determine 
which  factors  regulate  the  synthesis  of  the  ECM 
components in gastric carcinoma. 
Interleukin-11 (IL-11), a cytokine that exhibits a 
wide  variety  of  biological  effects  in  neutrophils  as 
well as in the haematopoietic and immune systems, is 
also involved in gastric cancer development[26]. The 
majority of gastric carcinomas express IL-11 and its 
receptor-α[27]. Sharing gp130 as a signalling mecha-
nism with several cytokines and growth factors, in-
cluding IL-6, oncostatin M, and leukaemia inhibitory 
factor (LIF), IL-11 promotes the migration of gastric 
cancer cells by the activation of the phosphatidylino-
sitol-3 kinase pathway[27, 28].  
IL-11 and versican have been independently re-
ported to be upregulated in gastric carcinomas[20, 21, 
29], suggesting a possible link between the upregula-
tion of these two species. Additionally, no study has 
been conducted to determine whether IL-11 has spe-
cific  effects  on  proteoglycan,  specifically  versican 
synthesis by gastric cancer cells. In this study, we in-
vestigated the differential expression of versican and 
its isoforms in gastric carcinoma tissue and cells, and 
analyzed  whether  treatment  with  exogenous  IL-11 
could  regulate  versican  synthesis  in  the  gastric  cell 
lines AGS and MKN45. Furthermore, we explored the 
effects of IL-11 on the migration and proliferation of 
AGS and MKN45 cells, and analyzed whether these 
effects were reversed when the expression of V0 and 
V1  were  abolished  by  siRNA  targeting  versican 
V0/V1. 
Materials and methods 
Clinical materials  
Fourteen freshly frozen tissue samples and the 
corresponding  normal  areas  adjacent  to  where  the 
tumour  specimens  (≥5cm)  were  taken  from  the  pa-
tients (ten men, four women; aged from 47-79 years, 
mean 64) with gastric cancer were collected. All of the 
patients  who  underwent  curative  resection  for  pri-
mary  gastric  adenocarcinomas  (referred  to  ‘‘gastric Int. J. Biol. Sci. 2012, 8 
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carcinoma’’  in  this  report)  were  operated  on  at 
Shanghai Changhai Hospital. All of the tissue speci-
mens  were obtained for the present  study  with  the 
patient’s  informed  consent.  The  collection  of  these 
tissue samples was undertaken with the approval of 
the  Changhai  Hospital  Institutional  Review  Board. 
Each tissue fragment was divided into two parts. One 
portion was processed for quantitative real-time PCR 
(Q-RT-PCR) analyses, the second portion for Western 
blot analyses, freezing them in liquid nitrogen.  
Cell culture 
The following human gastric carcinoma cell lines 
were used: AGS was purchased from American Type 
Culture Collection; MKN45, SH-10-TC, and HGC-27 
were obtained from Riken Bio Resource Centre; and 
MKN28, SGC-7901, MGc80-3, BGC-823, and GES were 
provided  by  the  Institute  of  Biochemistry  and  Cell 
Biology of the Chinese Academy of Science. All of the 
cells  were  maintained  in  RPMI  1640  (Biowest)  me-
dium  supplemented  with  10%  FBS  (Biowest),  100 
U/ml  penicillin,  100  μg/ml  streptomycin  sulphate, 
and 1 mM sodium pyruvate at 37°C in 5% CO2. The 
cells were passaged with trypsin-EDTA (0.05% tryp-
sin and 0.53 mM tetrasodium EDTA). 
To elucidate the effect of exogenous IL-11 on the 
regulation of versican isoforms, we performed treat-
ment assays with different concentrations of rhIL-11. 
The gastric carcinoma cells were seeded at an equal 
density in cell culture flasks containing growth me-
dium as described above. After 24 h, triplicate sam-
ples of subconfluent cells were treated with four dif-
ferent concentrations (0, 20, 50, 100 and 200 ng/ml) of 
activated rhIL-11 protein (R&D Systems, Minneapolis, 
MN,  USA)  and  incubated  for  24  h.  The  cells  were 
harvested to prepare mRNA and protein as described 
below. In the time-point assays, the cells were treated 
with 100 ng/ml of rhIL-11 and harvested at three dif-
ferent time points: hours 24, 48 and 72. 
RT-PCR and Q-RT-PCR 
The total RNA was isolated from frozen tissues, 
and cells were treated with the TRIzol (Takara, Da-
lian, China) method or left untreated according to the 
manufacturer’s  protocol.  The  RNA  quality 
(A260/A280  ratio)  and  quantity  were  determined 
using a standard spectrophotometer. One microgram 
of total RNA was used for cDNA synthesis using the 
RevertAidtm First Strand cDNA Synthesis Kit #1622 
(Fermentas,  Vilnius,  Lithuania)  according  to  the 
manufacturer’s  instructions.  Appropriate  forward 
and reverse primers to detect transcripts  of interest 
were  used  in  the  reverse  transcriptase  polymerase 
chain  reactions  (RT-PCRs)  for  cDNA  amplification. 
The  primer  sequences  for  GAPDH  were 
5´-CAAGGTCATCCATGACAACTTTG-3´  (forward) 
and 5´-GTCCACCACCCTGTTGCTGTAG-3´(reverse). 
The primer sequences for the versican V0, V1, V2, and 
V3  isoforms  were  previously  described[9]:  V0: 
5´-GACCTCAGGCGCTTTC-3´(forward)  and 
5´-CAGTGGTAACGAGATGCTTC-3´(reverse);  V1: 
5´-GCGCCACCCTGTGAC-3´(forward)  and  5´- 
CAGTGGTAACGAGATGCTTC-3´(reverse);  V2: 
5´-GACCTCAGGCGCTTTC-3´(forward)  and 
5´-TAGCACTGCCCTTGGA-3´(reverse);  V3: 
5´-TGAGAACCCTGTATCGTTTTGAGA-3´(forward) 
and  5´-CGTTAAGGCACGGGTTCATT-3´(reverse). 
The PCR conditions used for the amplification were as 
follows: 94 °C for 10 min, then 40 cycles of 94 °C for 30 
s, 55-58°C for 30 s, and 72°C for 45 s, followed by 72 °C 
for 10 min. The RT-PCR products were analysed on a 
1% agarose gel and visualised with ethidium bromide 
staining.  The  GAPDH  gene  was  used  as  a  positive 
control to assess the cDNA quality. 
Q-RT-PCR  was  conducted  using  a  7300  Re-
al-time  PCR  System  (Applied  Biosystems).  For  the 
semi-quantification  of  the  genes  of  interest,  we  uti-
lised the QPK-201 SYBR Green master mix (Toyobo, 
Osaka,  Japan).  The  target cDNA-specific  primers  of 
versican  isoforms  as  described  above  were  estab-
lished.  Standard  curves  were  plotted  for  each  opti-
mised assay, each of which produced a linear plot of 
the  threshold  cycle  (Ct)  against  log  (dilution).  The 
amount of each  target was quantified based on the 
concentration obtained from the standard curve and 
was presented in arbitrary units. The quantity of each 
target  was  normalised  against  the  quantity  of 
GAPDH. 
siRNAs preparation and Transfection 
The  siRNAs  to  human  versican  V0/V1  were 
chemically synthesised by Shanghai GenePharma Co., 
Ltd..  The  siRNA  sequences  for  the  indicated  genes 
were  designed  as  follows:  siRNA-V0/V1: 
5´-GAGGCUGGAACUGUUAUUATT-3´  (forward) 
and  5´-UAAUAACAGUUCCAGCCUCTT-3´  (re-
verse). The negative control dsRNA were as follows: 
5´-UUCUCCGAACGUGUCACGUTT-3´  (forward) 
and  5´-ACGUGACACGUUCGGAGAATT-3´  (re-
verse). 
According to the manufacturer’s specifications, 
the transfection of siRNA-V0/V1 was achieved with 
Lipo2000  (Invitrogen,  Gaithersburg,  MD)  in  6-well 
plates. In brief, one day before transfection, 2.0×105 
cells in 2 ml of growth medium without antibiotics 
were grown such that they would be 30-50% conflu-
ent at the time of transfection. The Lipo2000 diluted in 
Opti-MEMⅠ Reduced Serum medium (Gibco) with-Int. J. Biol. Sci. 2012, 8 
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out serum was used to supplement the dsRNA mix-
ture, and the formulation lasted for 25 min. Next, 6 μl 
of 20 μM dsRNA formulated with 8 μl Lipo2000 was 
added to a final volume of 2 ml Opti-MEMⅠ Reduced 
Serum medium. Cells were incubated at 37°C in a CO2 
incubator for 24-48 h. The medium was changed after 
6 h. 
Western blot analysis 
Whole-cell  lysates  were  prepared  from  human 
tissue specimens and treated cells. The insoluble tis-
sue debris was removed by centrifugation at 13,000×g 
at 4˚C for 15 min. The supernatant was collected, and 
the protein concentration was quantified using a pro-
tein  assay  reagent  (BCA,  Beyotime,  Shanghai).  The 
proteins were separated by SDS-PAGE, transferred to 
a  nitrocellulose  membrane  and  incubated  with  the 
polyclonal antibody anti-Versican V0/V1 Neo (Sigma, 
St. Louis, MO, USA), polyclonal antibody anti-human 
IL-11  (Peprotech,  NJ,  USA)  at  4°C  overnight.  The 
immunocomplexes were visualised using a horserad-
ish  peroxidase-conjugated  antibody  followed  by  a 
chemoluminescence reagent (Millipore, Billerica, MA, 
USA) and detected on photographic film. 
Cell proliferation assay 
The  AGS  and  MKN45  cells  were  treated  with 
rhIL-11 (100 ng/ml) at various time points (0, 24, 36, 
48, 60, and 72 h). And, after treated with siRNA for 24 
hours, the proliferation of AGS cells was also analysed 
at two time points (24 and 48h). The cell growth was 
determined by Cell Counting Kit-8 assay (R&S Bio-
technology, Shanghai) according to the manufacture’s 
protocol. Experiments were performed in triplicate. 
Scratch migration assay 
Scratch migration assays were performed as de-
scribed  previously[30,  31].  Briefly,  1.8×106  cells  per 
well were seeded in 6-well plates and incubated with 
growth medium as described above. After allowing 
the cells to adhere to the plates and reach 95% con-
fluence,  the  nearly  confluent  cell  monolayers  were 
scratched using yellow sterile pipette tips. Cells were 
then washed with PBS to remove the cellular debris, 
and the wounded monolayers were incubated in 5% 
FBS medium containing rhIL-11 (100 ng/ml) and bo-
vine serum albumin (BSA, 100 ng/ml) as a control. 
The  migration  of  the  cells  into  the  scratch  was  ob-
served by a blinded investigator and photographed at 
time points of 0 h, 12 h, 24 h, 36 h and 48 h. The dis-
tance  migrated  by  the  cells  was  quantitated  and 
compared  with  that  of  the  untreated  control  using 
statistical analyses. The experiments were repeated in 
duplicate wells at least three times. 
Transwell assay 
Transwell  assays  were  performed  using  poly-
carbonate transwell filters (Corning, 8μm) placed over 
the  bottom  chambers  that  were  filled  with  culture 
medium containing 20% FBS. The cells suspended in 
RPMI1640 medium containing 1% FBS were added to 
the upper chamber containing rhIL-11 (100 ng/ml) or 
BSA (100 ng/ml) as a control. A sample of 1.75×105 
cells  that  was  treated  for  24  h  with  a  siR-
NA-V0/V1/Lipo2000  mixture  and  a  NC/Lipo2000 
mixture was seeded into the upper well. After 48 h, 
cells on the upper surface of the well were removed, 
and  cells  on  the  lower  surface  were  fixed  in  cold 
methanol  and  stained  with  0.4%  crystal  violet.  For 
each experiment, the number of transmigrated cells in 
five random fields on the underside of the filter was 
counted  and  photographed,  and  three  independent 
filters were analysed. 
Statistic analysis 
Data were expressed as the mean±SD. The sta-
tistical  analyses  were  performed  using  a  Student’s 
t-test as indicated in the figure legends. A p value less 
than 0.05 was considered to be statistically significant. 
Results 
Identification of differential versican expres-
sion in gastric carcinoma tissue and cells 
Recently,  there  has  been  evidence  that  the  ex-
pression level of versican in gastrointestinal stromal 
tumours  is  significantly  higher,  and  the  highly  ex-
pressed  protein  is  correlated  with  poor  disease-free 
survival[20]. In our study, Q-RT-PCR was performed 
on  gastric  samples  to  screen  for  the  differential  ex-
pression of the versican isoforms. V1 exhibited a sig-
nificantly higher expression in the gastric carcinoma 
tissue than the other isoforms did (Fig. 1A; P<0.05). In 
the  RT-PCR  results,  the  isoforms  exhibited  profiles 
nearly identical to those obtained by Q-RT-PCR (Fig. 
1B). To further compare the differential expression of 
versican in the gastric tissue, all 28 gastric samples (14 
in situ carcinomas and 14 corresponding to adjacent 
normal  gastric  mucosa)  were  analysed  by  Western 
blot targeting versican V0 and V1. The results showed 
that V0/V1 revealed a significantly higher expression 
in  gastric  carcinoma  tissue  than  in  adjacent  normal 
tissue (Fig. 1C; P<0.05). Additionally, the expression 
profiles of versican isoforms were examined in nine 
human  gastric  carcinoma  cell  lines  by  means  of 
RT-PCR  at  the  mRNA  level,  using  GAPDH  as  the 
control gene.  Int. J. Biol. Sci. 2012, 8 
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Fig 1. Differential expression of versican and its isoforms. (A) Q-RT-PCR analysis of the expression of the versican mRNA isoforms in the 
gastric carcinoma tissue and the adjacent normal tissue samples. Four isoforms were analysed in the gastric carcinoma tissue and adjacent 
normal tissue. V1 revealed a significantly higher expression (*P<0.05). (B) RT-PCR analysis of the versican isoforms. The results agree well 
with those of the Q-RT-PCR analysis shown in Fig. 1 A. (C) The expression of versican V0/V1 was determined by Western blot. Versican 
was significantly up-regulated in gastric carcinoma tissue than in adjacent normal tissue (*P<0.05). GAPDH was used as the loading control. 
(D) Versican isoform variants in human gastric carcinoma cell lines. V0 and V1 were found to be expressed in most gastric cells. GAPDH 
was used to adjust for cDNA quantity. 
 
The experiments showed that most gastric car-
cinoma cell lines expressed the V0 and V1 isoforms in 
different amounts but with the same expression pat-
tern. V3 was expressed only slightly in some cell lines, 
whereas V2 was not found in any cell lines (Fig. 1D). 
These  findings,  which  are  consistent  with  the 
previous  results,  suggested  that  the  expression  of 
versican was significantly higher in gastric carcinoma 
tissue in comparison with the adjacent normal tissue, 
and  V0  and  V1  were  the  most  highly  expressed 
isoforms in these samples as well as some gastric car-
cinoma cell lines. 
Both V0 and V1 exhibit variant expression in 
cell culture after treatment with exogenous 
IL-11 
It  has  been  shown  that  cytokine  IL-11  can  in-
crease the proliferation and metastasis of gastric epi-
thelial  cells  and  promote  inflammation-associated 
gastric  tumourigenesis[29,  32].  Versican,  which  is 
regulated by many cytokines, is a TLR2 agonist and 
metastasis-enhancing  factor[33].  These  observations 
suggest that a possible link between IL-11 and versi-
can exists in gastric cells. Here we mainly studied the 
effect of rhIL11 on the versican V0 and V1 isoforms 
because they were the most highly expressed isoforms 
in the gastric tumours and cell lines. After treatment 
of AGS cells with four different concentrations (10, 50, 
100,  and  200  ng/ml)  of  rhIL-11,  V0  and  V1  both 
showed  a  significant  increase  in  a  concentra-
tion-dependent  manner  (Fig.  2A;  P<0.05,  P<0.01). 
Similarly, in MKN45 cells treated with 100 ng/ml of 
rhIL-11, the expression of V0 and V1 reached a peak of 
2.6-fold and 2.3-fold, respectively, and then decreased 
(Fig. 2A; P<0.05, P<0.01). Using Western blot, it was Int. J. Biol. Sci. 2012, 8 
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confirmed  that  the  expression  levels  of  versican 
V0/V1 in both cells, which treated with four different 
concentrations  of  rhIL-11,  kept  a  line  with  the 
Q-RT-PCR  results  (Fig.  2A).  To  investigate  the 
time-dependent regulation, three different time points 
(hours 24, 48 and 72) were used. Both V0 and V1 were 
upregulated in the two cell lines in a time-dependent 
manner  (Fig.  2B;  P<0.05,  P<0.01).  Moreover,  the 
western blot also showed a time-dependent upregu-
lation in both cells, which is consistent with results 
from the Q-RT-PCR analyses (Fig. 2B).  Collectively, 
these results suggested that IL-11 could regulate ver-
sican  synthesis  through  the  increase  of  V0  and  V1 
transcripts in both the AGS and MKN45 cell lines. 
 
Fig 2. Effects of exogenous IL-11 on the expression of the versican V0 and V1 isoforms in AGS and MKN45 cells. (A) Four different 
concentrations (10, 50, 100, and 200 ng/ml) of rhIL-11 were added to AGS and MKN45 cells. In AGS cells, V0 and V1 were both up-
regulated in a concentration-dependent manner. However, in MKN45 cells treated with 100 ng/ml of rhIL-11, V0 and V1 reached peak 
expression levels of 2.6-fold and 2.3-fold, respectively (*P<0.05, **P<0.01). (B) After treatment of AGS and MKN45 cells with rhIL-11 (100 
ng/ml) at three different time points (hours 24, 48 and 72), V0 and V1 were both upregulated in a time-dependent manner (*P<0.05, 
**P<0.01). The quantity of each target was normalised against the quantity of GAPDH. Mean values of the control group were set to a 
value of 1. n=3. Results are given as the mean±SD. Int. J. Biol. Sci. 2012, 8 
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Exogenous IL-11 increases migration and pro-
liferation in gatric carcinoma cell lines  
To determine if exogenous IL-11 has an effect on 
gastric  carcinoma  cells,  a  transwell  assay  was  per-
formed to assess the migration of AGS cells. In the 
absence or presence of rhIL-11 (100 ng/ml), AGS cells 
showed differential migration efficiency. Exposure to 
rhIL-11  induced  the  migration  rate  of  AGS  cells  in 
spheroid assays more significantly than the untreated 
control  and  BSA  (Fig.  3A;  Fig.  3B;  P<0.01)  did.  In 
CCK-8 proliferation assay, both cell lines which were 
treated with rhIL-11 (100 ng/ml) didn’t show signifi-
cantly  proliferation  until  60  hours  (Fig.  3C;P<0.05, 
P<0.01). A scratch migration assay was also used to 
validate  the  effects  of  rhIL-11  on  AGS  and  MKN45 
cells migration. The migration rate was quantitatively 
assessed at different time points (0, 12, 24, 36 and 48 
h). By 36 h, there was an apparent difference in both 
cells, as shown in Fig. 3D. Similarly, the cells treated 
with  rhIL-11  (100  ng/ml)  migrated  into  the  wound 
with a significantly decreased distance between the 
edges as compared to the untreated control (Fig. 3D). 
 
 
 
Fig 3. Effect of exogenous IL-11 on the migration and proliferation of gatric carcinoma cell lines. (A) The directed migratory capacities of 
AGS cells treated with rhIL-11 were evaluated using a Transwell migration study. Sample images showing the pro-migratory effect of IL-11 
on AGS cells after staining the transmigrated cells with crystal violet (magnification, ×100). Exogenous IL-11 induced migration more 
significantly than the untreated control and BSA did. (B) Graphs indicate the average number of cells from five random high-power fields 
in the indicated groups. Data are presented as mean±SD based on three independent experiments (**P<0.01). (C) Proliferative effects of 
rhIL-11 in gatric carcinoma cell lines (AGS and MKN45 cells) were measured by CCK-8 assay. Both cell lines exhibited significantly growth 
until 60 hours (*P<0.05, **P<0.01). (D) A scratch migration assay was used to assess the migration of AGS and MKN45 cells that were 
treated with rhIL-11 (100 ng/ml). The migration rate was quantified by measuring the distance between the edges of the scratch at t=0 
relative to t=36 h. After incubation, the cells can be seen migrating into the wound with a decreased distance between the edges. 
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Abnormally expressed versican participates in 
gastric carcinoma progression mediated by 
exogenous IL-11  
Because  versican  and  IL-11  had  the  same 
pro-migratory  characteristics  in  gastric  carcinoma 
cells  and  because  the  versican  isoforms  V0  and  V1 
were upregulated by IL-11, it was of high interest to 
assess whether versican participates in gastric carci-
noma progression mediated by IL-11. To address this 
question, we performed transwell assays on the AGS 
cells transfected  with  the  inhibitory siRNA-versican 
or  the  corresponding  NC  siRNA.  After  transfection 
with siRNA for 24 h, the cells were treated with IL-11 
(100 ng/ml) or BSA (100 ng/ml) in parallel in the two 
assays.  
At the molecular level, V0 and V1 gene expres-
sion were significantly decreased, which was verified 
by realtime PCR (Fig. 4A). In parallel, a quantitative 
evaluation  of the  inhibition of versican V0/V1 pro-
teins levels in AGS cells was analysed by a Western 
blot analysis (Fig. 4B). At the gene level, the results 
were  consistent  with  those  at  the  protein  level  and 
revealed  that  siRNA-versican  inhibits  versican  ex-
pression markedly, but the NC siRNAs do not result 
in inhibition. And under the same condition, the ex-
pression of endogenous IL-11 did not been affected by 
siRNAs transfection (Fig. 4B). Moreover, after trans-
fected with siRNAs, the cells viability did not reveal a 
significantly difference, at least within 48 hours (Fig. 
4C; P>0.05). In the transwell assay, neither BSA nor 
the  NC  siRNAs  showed  any  influence  on  AGS  cell 
migration (Fig. 4D; Fig. 4E; Fig. 3A).  
 
 
Fig 4. (A): Q-RT-PCR was performed to validate versican V0 and V1 inhibition after AGS cells were transfected with siRNA-versican. (B) 
Western blot analysis of versican V0/V1 and IL-11 protein levels. The results in (A) and (B) showed that versican V0/V1 were significantly 
inhibited by siRNA-V0/V1 but not by the negative control siRNA in AGS cells, and the expression of endogenous IL-11 in cells was not 
affected by both siRNAs. (C) The cell viability of siRNAs transfected was measured by CCK-8 assay. In both 24 and 48h time points, the 
cell viability didn’t show a significantly difference between siRNAs treated and untreated control groups (P>0.05). (D) The effect of 
versican on AGS cell migration mediated by rhIL-11 was analysed in a transwell assay as described in the methods section. rhIL-11-treated 
cells showed significantly higher migration rates (**P<0.01). siRNA-versican was able to decrease migration, both with and without 
rhIL-11, compared to the untreated control and BSA (**P<0.01). (E) The migrated cells were quantified and expressed as the mean±SD 
of three independent experiments. Int. J. Biol. Sci. 2012, 8 
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Additionally,  after  being  transfected  with  NC 
siRNAs, the cells revealed a significantly higher mi-
gration  rate  in  the  presence  of  rhIL-11  (100  ng/ml) 
compared  to  untreated  controls  (Fig.  4D;  Fig.  4E; 
P<0.01).  However,  following  treatment  with  siR-
NA-versican, the enhanced migration of the cells by 
rhIL-11 was reversed. When IL-11 (100 ng/ml) was 
added,  the  migration  of  the  siRNA-versican-treated 
cells decreased relative to the untreated control (Fig. 
4D; Fig. 4E; P<0.01). 
Collectively, these results led the authors to con-
clude that both versican and IL-11 play an important 
role in regulating the migration of malignant gastric 
cells, and versican, together with IL-11, participates in 
the regulation of gastric cell migration. 
Discussion 
In the present study, our results agree well with 
previous  reports  of  significantly  elevated  versican 
expression in human gastric carcinomas relative to the 
adjacent normal gastric mucosa[20-22]. Versican me-
diates cell-ECM interaction and the stable expression 
of it enhances cell attachment and the expression of β1 
integrin  and  fibronectin[34].  It  has  been  suggested 
that the abnormal expression of versican is related to 
cell proliferation, differentiation, adhesion, and even 
the  homeostasis  and  integrity  of  the  ECM[5].  The 
up-regulated  versican,  interacting  with  its  partners, 
modulate the organization of the ECM and promote 
tumor growth[9, 24]. While versican V0/V1 silencing 
has been suggested to cause a decrease in cell prolif-
eration and migration, both in wound healing assays 
and in transwell chambers[35]. So, the elevated ver-
sican may be obligatory for angiogenesis and metas-
tasis  in  tumours[19].  Metastasis  is  the  most  critical 
aspect of tumourigenesis, and more than 90% of can-
cer  mortality  is  caused  by  metastasis[36].  Recent 
studies  unambiguously  show  that  the  extracellular 
matrix  component  versican,  which  activates  macro-
phages  through  Toll-like  receptor  (TLR)  2  and  its 
co-receptors  TLR6  and  CD14,  strongly  enhances 
Lewis  lung  cell  carcinoma  metastasis[33].  Thus,  to 
some extent, one can say that versican is a metasta-
sis-enhancing factor. 
The four identified versican isoforms and their 
differential expression have been observed in multi-
ple human cancers. It has been suggested that all four 
isoforms were significantly overexpressed in human 
breast  cancer[37].  Additionally,  higher  steady-state 
levels of mRNA transcripts and gene products of the 
versican variants V0, V1, and V3 were detected in the 
nodular tissues than in the non-nodular parenchyma 
of  benign  prostatic  hyperplasia[38].  The  differential 
expression  of  specific  isoforms  may  be  involved  in 
and even influence tumour cell behaviour[39, 40]. For 
instance, all melanoma cell lines with an early or in-
termediate degree of differentiation expressed V0 and 
V1 isoforms, whereas V2 and V3 expression were ob-
served only in undifferentiated cell lines[41]. Syrokou 
et al. have proved that the synthesis and expression of 
mRNA encoding for different versican splice variants 
were related to the aggregation of human epithelial 
mesothelioma cells[42]. In our present work, the dif-
ferential expression of versican isoforms was detected 
for the first time, and V0 and V1 were found to be the 
predominant isoforms present in gastric samples as 
well as some gastric carcinoma cell lines.  Our find-
ings,  which  were  consistent  with  previous  reports, 
suggested that the differential expression of specific 
isoforms may participate in the progression of gastric 
carcinoma. 
Next, we showed that the exogenous IL-11 alone 
could increase the migration and proliferation of the 
gastric carcinoma cell lines. This corresponds to pre-
vious data that IL-11 acts as a cell mitogen and up-
regulates the invasive activity of human gastric car-
cinoma  cells[27,  29].  Through  proangiogenic  and 
pro-proliferative mechanisms, IL-11 has been impli-
cated  in  gastric  restitution[43,  44].  Merchant  sug-
gested  that  IL-11,  via  Stat3,  promotes  inflamma-
tion-associated gastric tumourigenesis[45]. Addition-
ally, Ernst et al. also reinforced the critical importance 
of  the  IL-11/Stat3  signal  transduction  pathway  in 
gastric tumours in mice[32]. IL-11 and versican have 
been  individually  implicated  in  tumour  progres-
sion[20, 21, 29], but their potential regulations or in-
teractions under these conditions have not been con-
sidered. Thus, the knowledge that these two species 
are regulated or mediated by each other may further 
our understanding of their functions in cancer. 
Interestingly, in our research, we demonstrated 
that exogenous IL-11 could directly affect the expres-
sion  of  the  versican  variants  both  in  the  AGS  and 
MKN45 cell lines, favouring the GAG-rich variants. 
Furthermore, the expression of versican V0/V1 was 
markedly  inhibited  by  siRNA-versican,  and  the  en-
hanced migration of the cells by IL-11 was reversed. 
Perhaps the most intriguing question that needs fur-
ther investigation is how versican expression is regu-
lated  by  exogenous  IL-11.  IL-11  could  regulate  epi-
thelial cell turnover by STAT3 and ERK1/2 depend-
ent pathway[29].  And versican interacts with  EGFR 
through its C-terminal globular domains[9]. In addi-
tion, treatment with rhIL-11 stimulated expression of 
several MMPs (Matrix Metallo Proteinases) in stomachs 
of wild-type mice[46]. While MMP types -1, -2, -3, -7, 
and  -9, have also been shown to cleave versican in 
vitro[47,  48].  So,  by  bridge  of  STAT3  and  ERK1/2 Int. J. Biol. Sci. 2012, 8 
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signalling or MMPs, IL-11 may regulate the synthesis 
of versican, at least partly. Nevertheless, on the basis 
of  the  achieved  results,  one  can  propose  that  the 
IL-11-induced migration change was, to some extent, 
a result of elevated versican. 
These results not only support the proposed role 
of versican as a proliferative and pro-migratory mol-
ecule, but also prove that IL-11 triggers the malignant 
phenotype of gastric carcinoma cells by the induction 
of migration and that this effect is mediated by versi-
can  V0/V1.  Thus,  our  research,  which  is  consistent 
with  previous  studies,  demonstrates  that  IL-11  can 
regulate the expression of versican and its variants in 
gastric  cell  lines,  and  versican,  together  with  IL-11, 
participates in the regulation of gastric cell migration. 
Alternatively, our results suggest that some growth 
factors or cytokines that act as important mediators of 
inflammation might exert their effects first on the ex-
tracellular  matrix  components,  such  as  versican,  to 
create  a  hostile  microenvironment  for  tumour  pro-
gression  or  subsequent  steps  of  inflammation.  The 
identification of the nature of the interaction of versi-
can  with  these  and  other  inflammatory  mediators 
awaits further study. 
In  conclusion,  our  study  demonstrates,  for  the 
first time, the differential expression of versican var-
iants in gastric samples as well as some gastric carci-
noma cell lines and the alterations in the mRNA pat-
terns of V0 and V1 isoforms when cells are treated 
with  rhIL-11.  IL-11  promotes  the  malignant  pheno-
type of gastric carcinomas by the induction of migra-
tion, and this effect is, at least in part, mediated by 
versican V0/V1. 
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